Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors:
SEC Accession No. 0001213900-25-116693
Filing Date
2025-12-01
Accepted
2025-12-01 16:15:11
Documents
1

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G  
1 primary_doc.xml SCHEDULE 13G 6059
  Complete submission text file 0001213900-25-116693.txt   7724
Mailing Address 101-1220 WEST 6TH AVENUE VANCOUVER, BRITISH COLUMBIA Z4 V6H1A5
Business Address 101-1220 WEST 6TH AVENUE VANCOUVER, BRITISH COLUMBIA Z4 V6H1A5 972-54-5704749
Clearmind Medicine Inc. (Subject) CIK: 0001892500 (see all company filings)

EIN.: 000000000 | State of Incorp.: Z4 | Fiscal Year End: 1031
Type: SCHEDULE 13G | Act: 34 | File No.: 005-93839 | Film No.: 251539829
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address RAOUL WALLENBERG 20 TEL AVIV L3 6971916
Business Address RAOUL WALLENBERG 20 TEL AVIV L3 6971916 972-505-501574
Capitalink Ltd. (Filed by) CIK: 0002036836 (see all company filings)

EIN.: 000000000 | State of Incorp.: L3 | Fiscal Year End: 1231
Type: SCHEDULE 13G